Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/178)
-
Publication number: 20120058981Abstract: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject.Type: ApplicationFiled: October 17, 2011Publication date: March 8, 2012Inventors: Robert E. Dudley, Dominique Drouin
-
Patent number: 8124118Abstract: The present invention relates to a drug carrier composition comprising i) one or more biodegradable hydrating ceramics ii) one or more expandable agents, and iii) sorbed aqueous medium which in solid form has a ruptured structure. The function of the expandable agent is to create a ruptured structure in the solidified composition, either a foam-like structure or a disintegrated structure where it is split into a large number of parts, particles, units, granules or pieces, so as to obtain an enlarged apparent surface area that is exposed to degradation or erosion upon administration. Suitable substances to obtain this surface enlarging effect are gas-forming agents or swelling agents, gelling agents or disintegrants, here referred to as expandable agents. The expandable agents may be bioresorbable or non-bioresorbable.Type: GrantFiled: October 21, 2004Date of Patent: February 28, 2012Assignee: Lidds ABInventors: Hans Lennernäs, Bo Lennernäs, Jonas Hugosson, Niklas Axén
-
Patent number: 8124129Abstract: There is provided a hemihydrate of (3?,5?,7?,12?)-7,12-dihydroxy-3-{2-[{4-[17?-hydroxy-3-oxo-17?-prop-1-ynylestra-4,9-dien-11?-yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2?=6.58±0.2, 8.54+0.2, 12.28±0.2, and 19.68±0.2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response.Type: GrantFiled: July 12, 2006Date of Patent: February 28, 2012Assignee: Karo Bio ABInventors: Russell Drew Cink, Daozhong Zou, Marvin Robert Leanna, Pascal H. Toma, Michelle Andrée Long
-
Publication number: 20120046261Abstract: Disclosed herein are compositions and methods of identifying a subject at risk for preterm birth and selecting effective therapies for preventing preterm birth in the subject. The disclosed methods generally involve determining the identity of one or more nucleotides in the progesterone receptor (PR) gene of the subject.Type: ApplicationFiled: February 24, 2010Publication date: February 23, 2012Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Tracy Ann Manuck, Michael W. Varner
-
Publication number: 20120046262Abstract: Disclosed herein is a method of using megestrol acetate. In one embodiment, the method comprises informing a user that megestrol acetate is metabolized by a cytochrome p450 isozyme. In another embodiment, the method comprises obtaining megestrol acetate from a container associated with published material providing information is metabolized by a cytochrome p450 siozyme. Also disclosed are articles of manufacture comprising a container containing a dosage form of megestrol acetate, wherein the container is associated with published material informing that megestrol acetate is metabolized by a cytochrome p450 siozyme, a method of treatment, and a method of manufacturing a megestrol acetate product.Type: ApplicationFiled: October 12, 2011Publication date: February 23, 2012Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventor: Matthew William Davis
-
Patent number: 8119619Abstract: Steroid compounds possessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.Type: GrantFiled: January 7, 2011Date of Patent: February 21, 2012Assignee: Umecrine ABInventors: Torbjörn Bäckström, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
-
Publication number: 20120040901Abstract: The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps: 1. contacting the anionic polymeric component and an cyclodextrin component in an aqueous medium, and 2. adding to the mixture obtained in step 1 said amphiphilic ammonium-type component, wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cyclodextrin component. Both types of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulations suitable for long-lasting delivery of said further components.Type: ApplicationFiled: October 25, 2011Publication date: February 16, 2012Inventors: Lajos Szente, Jozsef Szejtli, György Lajos Kis, Christian Schoch
-
Publication number: 20120028946Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: October 5, 2011Publication date: February 2, 2012Inventors: Ramana Malladi, Jodi Miller
-
Publication number: 20120027864Abstract: The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations.Type: ApplicationFiled: October 7, 2011Publication date: February 2, 2012Applicant: WESTERN UNIVERSITY OF HEALTH SCIENCESInventor: Guru V. BETAGERI
-
Publication number: 20120030779Abstract: Disclosed herein is a non-human animal model of protein aggregation cardiomyopathy. Also disclosed are compo-sitions and methods of treating or preventing a condition in a subject caused or exacerbated by reductive stress. Also disclosed are compositions and methods of predicting, detecting, or monitoring reductive stress in a subject.Type: ApplicationFiled: January 18, 2008Publication date: February 2, 2012Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDTIONInventors: Ivor J. Benjamin, Namakkal S. Rajasekaran, Thomas P. Kennedy
-
Publication number: 20120022033Abstract: Methods for decreasing the risk of cardiovascular events in postmenopausal women having a high risk for a cardiovascular event are provided. In particular, methods for decreasing the risk of cardiovascular events in postmenopausal woman at high risk for cardiovascular events by administering to the woman a therapeutically effective amount of an androgen, whereby administering the androgen decreases the risk of cardiovascular events in the woman compared to untreated postmenopausal woman at high risk for cardiovascular events are provided.Type: ApplicationFiled: July 20, 2011Publication date: January 26, 2012Applicant: BIOSANTE PHARMACEUTICALS, INC.Inventors: Stephen Simes, Michael Snabes, Joanne Zborowski
-
Publication number: 20120014915Abstract: The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these ThI-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the postpartum period.Type: ApplicationFiled: September 26, 2006Publication date: January 19, 2012Inventor: Rhonda Voskuhl
-
Publication number: 20120010176Abstract: Methods are provided for increasing utrophin promoter activity, utrophin expression or utrophin activity, and treating or reducing the symptoms of muscular dystrophy by administering to a subject in need thereof an effective amount of a composition comprising a utrophin promoter or activity upregulator. Muscular dystrophy includes but is not limited to Duchenne muscular dystrophy, Becker's muscular dystrophy, limb girdle muscular dystrophy, or a disease characterized by mutation or dysregulation of the dystrophin gene or an aberrant or dysfunctional dystrophin.Type: ApplicationFiled: November 12, 2009Publication date: January 12, 2012Inventors: Tejvir S. Khurana, Scott L. Diamond, Catherine Moorwood, Olga Lozynska, Andrew D. Napper, Emidio Pistilli, Neha Suri
-
Publication number: 20120003158Abstract: The present invention provides various biomarkers of inflammatory bowel disease, including biomarkers for Crohn's disease and biomarkers for Ulcerative colitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of inflammatory bowel disease, methods for distinguishing between inflammatory bowel diseases, methods of determining predisposition to inflammatory bowel disease, methods of monitoring progression/regression of inflammatory bowel disease, methods of assessing efficacy of compositions for treating inflammatory bowel disease, methods of screening compositions for activity in modulating biomarkers of inflammatory bowel disease, methods of treating inflammatory bowel disease, as well as other methods based on biomarkers of inflammatory bowel disease.Type: ApplicationFiled: April 8, 2011Publication date: January 5, 2012Inventors: Danny ALEXANDER, Jeffrey SHUSTER, Joshua KORZENIK, Garrett ZELLA
-
Publication number: 20120004169Abstract: The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the invention concerns methods of inhibiting the growth of a tumor by administering a cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the JAK/STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the JAK and/or STAT3 signaling pathways in vitro or in vivo using cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the present invention concerns a method for screening candidate compounds for JAK and/or STAT3 inhibition and anti-tumor activity.Type: ApplicationFiled: August 15, 2011Publication date: January 5, 2012Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: SAID M. SEBTI, Richard Jove
-
Patent number: 8088758Abstract: 3,15-substituted estrone compounds which act as inhibitors of 17?-hydroxysteroid dehydrogenase type I (17?-HSD1), salts thereof, pharmaceutical preparations containing such compounds, processes for preparing such compounds, and therapeutic uses of such compounds, particularly in the treatment or inhibition of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17?-hydroxysteroid dehydrogenase type I enzymes and/or requiring the lowering of the endogenous 17?-estradiol concentration, as well as the general use of selective 17?-hydroxysteroid dehydrogenase type 1 inhibitors which possess in addition no or only pure antagonistic binding affinities to the estrogen receptor for the treatment or inhibition of benign gynecological disorders, particularly endometriosis.Type: GrantFiled: November 9, 2004Date of Patent: January 3, 2012Assignee: Abbott Products GmbHInventors: Josef Messinger, Heinrich-Hubert Thole, Bettina Husen, Bartholomeus Johannes Van Steen, Gyula Schneider, Johannes Bernardus Everardus Hulshof, Pasi Koskimies, Nina Johansson, Jerzy Adamski
-
Publication number: 20110319373Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: ApplicationFiled: July 25, 2011Publication date: December 29, 2011Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, OTONOMY, INC.Inventors: Jay Lichter, Benedikt Vollrath, Andrew M. Trammel, Sergio G. Durón, Fabrice Piu, Luis A. Dellamary, Qiang Ye, Carl Lebel, Michael Christopher Scaife, Jeffrey P. Harris
-
Publication number: 20110319375Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: ApplicationFiled: July 25, 2011Publication date: December 29, 2011Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, OTONOMY, INC.Inventors: Jay Lichter, Benedikt Vollrath, Sergio G. Durón, Michael Christopher Scaife, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Andrew M. Trammel, Jeffrey P. Harris
-
Publication number: 20110319376Abstract: Methods, formulations, and devices for providing transdermal or transmucosal delivery of testosterone to female subjects in need thereof. The formulations and methods treat symptoms of hormonal disorders including hypogonadism, female sexual desire disorder, female menopausal disorder, and adrenal insufficiency.Type: ApplicationFiled: September 7, 2011Publication date: December 29, 2011Inventors: Leah M. Lehman, Stephen M. Simes
-
Publication number: 20110319374Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: ApplicationFiled: July 25, 2011Publication date: December 29, 2011Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, OTONOMY, INC.Inventors: Jay Lichter, Benedikt Vollrath, Sergio G. Durón, Michael Christopher Scaife, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Andrew M. Trammel, Jeffrey P. Harris
-
Publication number: 20110306582Abstract: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject.Type: ApplicationFiled: June 21, 2011Publication date: December 15, 2011Inventors: Robert E. Dudley, Dominique Drouin
-
Publication number: 20110306583Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: July 11, 2011Publication date: December 15, 2011Inventor: Ramana Malladi
-
Publication number: 20110306539Abstract: A process for making particles for delivery of drug nanoparticles is disclosed herein. The process comprises the steps of (a) forming a suspension of drug nanoparticles by mixing a precipitant solution with an anti-solvent solution under micro-mixing environment, where the formed nanoparticles have a narrow particle size distribution; (b) providing an excipient to at least one of the precipitant solution, the anti-solvent solution and the suspension of drug nanoparticles, the excipient being selected to maintain said drug nanoparticles in a dispersed state when in liquid form; and (c) drying the suspension of drug nanoparticles containing the excipient therein to remove solvent therefrom, wherein removal of the solvent causes the excipient to solidify and thereby form micro-sized matrix particles, each micro-sized particle being comprised of drug nanoparticles dispersed in a solid matrix of the excipient.Type: ApplicationFiled: September 24, 2009Publication date: December 15, 2011Inventors: Zhigang Shen, Jimmy Sung Lai Yun, Jun Hu, Arvind Jugade, Jiyao Zhang, Wenhao Chen, Zhe Wang, Lingyan Gao, Jian Feng Chen
-
Patent number: 8076316Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: December 1, 2010Date of Patent: December 13, 2011Assignee: Harbor BioSciences, Inc.Inventor: James M. Frincke
-
Publication number: 20110293556Abstract: This invention relates to Applicant's discovery that Metabolic Syndrome , a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with ?-amyloid protein for the TDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals.Type: ApplicationFiled: August 8, 2011Publication date: December 1, 2011Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventors: Stuart A. LIPTON, Daniel EINHORN
-
Publication number: 20110286998Abstract: Methods are provided for treating HPG axis-positive cancers, preventing or slowing proliferation of cells of HPG axis-positive cancer origin, preventing HPG axis-positive cancers in a patient at risk of contracting such cancers, preventing or inhibiting an upregulation of the cell cycle in HPG axis-positive cancer-derived cells in a patient, and decreasing the level of HPG axis-positive cancer-specific markers in a patient.Type: ApplicationFiled: November 19, 2010Publication date: November 24, 2011Applicant: Voyager Pharmaceutical CorporationInventors: Christopher W. Gregory, Maria E. Kononov, Eric S. Werdin, James Lester Barbee, IV, Carol Giamario
-
Publication number: 20110275558Abstract: The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs.Type: ApplicationFiled: May 4, 2011Publication date: November 10, 2011Applicant: Virginia Tech Intellectual Properties, Inc.Inventors: Josep BASSAGANYA-RIERA, Pinyi LU, Raquel HONTECILLAS
-
Publication number: 20110269729Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: July 11, 2011Publication date: November 3, 2011Inventor: Ramana Malladi
-
Publication number: 20110268806Abstract: The present invention relates to a antisolvent solidification process wherein a liquid medium comprising at least one organic or inorganic compound which is to be solidified is forced through a membrane into one or more antisolvents, or wherein one or more antisolvents are forced through a membrane into a liquid medium comprising at least one organic or inorganic compound which is to be solidified, yielding a composition comprising solid particles comprising said organic and/or inorganic compound(s).Type: ApplicationFiled: May 3, 2011Publication date: November 3, 2011Applicant: Organon USA, Inc.Inventors: Wridzer Jan Willem Bakker, Robert Michael Geertman, Marianne Frederika Reedijk, Jozef Johannes Maria Baltussen, Gerrald Bargeman, Cornelis Elizabeth Johannus Van Lare
-
Patent number: 8048441Abstract: Medical devices comprising nanobeads encapsulating one or more bioactive agents and methods of use thereof are provided.Type: GrantFiled: June 25, 2007Date of Patent: November 1, 2011Assignee: Abbott Cardiovascular Systems, Inc.Inventors: Charles H. Craig, John E. Papp, Dudley Jayasinghe, Lionel G. Hines, Dennis Orosa
-
Publication number: 20110262543Abstract: Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared.Type: ApplicationFiled: April 21, 2011Publication date: October 27, 2011Applicant: Chiesi Farmaceutici S.p.A.Inventors: Daniela Cocconi, Rossella Musa
-
Publication number: 20110257141Abstract: This invention relates to novel transdermal or transmucosal pharmaceutical formulation having an active agent of testosterone which reduces the occurrences of contamination of other individuals and the transference to clothing of the user. The solvent system of the formulation includes a monoalkylether of diethylene glycol and a glycol present in specified ratios, and a mixture of water and alcohol. The invention also relates to a method for inhibiting or delaying crystallization of the active agent in a pharmaceutical formulation.Type: ApplicationFiled: May 12, 2011Publication date: October 20, 2011Inventors: Dario Norberto R. Carrara, Arnaud Grenier
-
ORAL TESTOSTERONE ESTER FORMULATIONS AND METHODS OF TREATING TESTOSTERONE DEFICIENCY COMPRISING SAME
Publication number: 20110251167Abstract: A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.Type: ApplicationFiled: April 12, 2010Publication date: October 13, 2011Inventors: Robert E. Dudley, Panayiotis P. Constantinides -
Publication number: 20110245215Abstract: A formulation for transdermal or transmucosal administration of an active agent. The formulation includes an active agent and a delivery vehicle comprising a C2 to C4 alkanol, a polyalcohol, and a permeation enhancer of monoalkyl ether of diethylene glycol present in an amount sufficient to provide permeation enhancement of the active agent through dermal or mucosal surfaces. The formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters in order to avoid undesirable odor and irritation effects caused by such compounds during use of the formulation. Also, the active agent is testosterone that is present in an amount of about 1%, the alkanol is ethanol that is present in an amount of about 46.28% to about 47.5% of the formulation; the polyalcohol is propylene glycol that is present in an amount of about 6% of the formulation; and the permeation enhancer is diethylene glycol monoethyl ether that is present in an amount of about 5% of the formulation.Type: ApplicationFiled: May 12, 2011Publication date: October 6, 2011Inventors: Dario Norberto R. Carrara, Arnaud Grenier, Celine Besse, Stephen M. Simes, Leah M. Lehman
-
Patent number: 8030297Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: GrantFiled: May 14, 2009Date of Patent: October 4, 2011Assignees: Otonomy, Inc., The Regents of the University of CaliforniaInventors: Jay Lichter, Andrew M. Trammel, Jeffrey P. Harris, Fabrice Piu, Carl Lebel, Qiang Ye, Luis A. Dellamary
-
Patent number: 8030296Abstract: There is provided a compound of Formula I wherein X is a ring system; R1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; R2 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein when X is a steroidal structure and both of R1 and R2 are sulphamate groups, the steroidal ring system (X) represents an oestrogen; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth.Type: GrantFiled: March 3, 2006Date of Patent: October 4, 2011Assignee: Sterix LimitedInventors: Barry Victor Lloyd Potter, Michael John Reed, Lok Wai Lawrence Woo, Hatem Hejaz, Bertrand Leblond, Matthew Paul Leese, Atul Purohit
-
Publication number: 20110237562Abstract: The present invention relates to the use of a container, made of an inorganic additive containing plastic material, for reducing physical/chemical interaction between the container and an oil, fat and/or wax containing formulation contained therein.Type: ApplicationFiled: June 3, 2011Publication date: September 29, 2011Applicant: Udo MatternInventor: Claudia MATTERN
-
Patent number: 8026229Abstract: The present invention relates to the use of 2-alkoxyestrogen sulfamates of general formula I wherein R1 and R2 independently represent H, methyl, C1-C4 acyl, benzoyl R3 represents C1-C4 alkyl or a group of formula CnFmHo, wherein n=1, 2, 3, 4, 5 or 6, m>1, and m+o=2n+1, R4 and R5 in each case represent H or, together, a methylene group or an additional double bond, R6 represents H, R7 represents OH, OC1-C4-alkyl, OC1-C11-acyl or OSO2NR1R2, the dashed lines in the B and C rings of the steroid skeleton additionally representing up to two double bonds, for the production of a medical drug for the treatment of tumor diseases which can be affected positively by inhibiting the tubulin polymerization. The inventive compounds are distinguished by the 2-alkoxy substitution in conjunction with the 17-hydroxy substitution. They have a special effect with regard to inhibiting tubulin polymerization and can be used, for example, for the treatment of prostate cancers.Type: GrantFiled: August 13, 2002Date of Patent: September 27, 2011Assignee: Sterix LimitedInventors: Ina Scherlitz-Hofmann, Jens Hoffmann, Alexander Hillisch, Eberhard Unger, Tobias Neumann, Sigfrid Schwarz, Olaf Peters, Thomas Michel
-
Publication number: 20110223217Abstract: An encoding/decoding apparatus and method using a low-density parity-check code (LDPC code) is disclosed. Basic column group information, serving as a set of information regarding positions of rows with weight 1, is extracted from a reference column in each column group of a predetermined parity-check matrix. Column group information transforms the positions of rows with weight 1 into positions whose lengths are within a required parity length. A parity-check matrix is generated according to the generated column group information. Data is encoded or decoded based on the generated parity-check matrix.Type: ApplicationFiled: November 24, 2009Publication date: September 15, 2011Applicant: Ecole Polytechnique Federale de Lausanne (EPFL)Inventors: James Brandon Dixon, Jeffrey A. Hubbell, Conlin P. O'Neil, Melody Swartz, Diana Velluto
-
Publication number: 20110212935Abstract: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?-hydroxy-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 3?-hydroxy-16?-fluoro-17?-aminoandrost-5-ene, 1?,3?-dihydroxy-4?-fluoroandrost-5-ene-17-one, 1?,3?,17?-trihydroxy-4?-fluoroandrost-5-ene, 1?,3?-dihydroxy-6?-bromoandrost-5-ene, 1?-fluoro-3?,12?-dihydroxyandrost-5-ene-17-one, 1?-fluoro-3?,4?-dihydroxyandrost-5-ene and 4?-fluoro-3?,6?,17?-trihydroxyandrostane.Type: ApplicationFiled: April 27, 2011Publication date: September 1, 2011Applicant: Harbor BioSciences, Inc.Inventor: James M. Frincke
-
Publication number: 20110201586Abstract: A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.Type: ApplicationFiled: March 24, 2011Publication date: August 18, 2011Inventors: Robert E. Dudley, Dominique Drouin
-
Publication number: 20110201585Abstract: A method of reducing or inhibiting the risk of infection from sexually transmitted viral infections (STIs), such as HIV and HPV, comprising the topical administration of oestrogenic compounds, analogues or metabolites thereof or oestrogen agonists to a human penis. A method to increase keratinisation of the penile epithelium is also provided. Suitable formulations are also provided.Type: ApplicationFiled: May 9, 2008Publication date: August 18, 2011Inventors: Roger Short, Andrew Pask
-
Publication number: 20110200678Abstract: The present invention relates to a novel technology for forming fine particles with a size of 0.02˜3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.Type: ApplicationFiled: March 3, 2010Publication date: August 18, 2011Applicant: THE INDUSTRY METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTIOInventors: Sung Joo Hwang, Min Soo Kim, Jeong Soo Kim, Kwang Ho Cha, Won Kyung Cho, Jun Sung Park, Suk Jun Seo
-
Publication number: 20110195942Abstract: Methods of using 7?,11?-dimethyl-17?-hydroxy-4-estren-3 -one bucyclate (I) and 7?,11?-dimethyl-17?-hydroxyestr-4-en-3-one 17-undecanoate (II) for various hormonal therapies, dosage forms comprising 7?,11?-dimethyl-17?-hydroxy-4-estren-3-one bucyclate and 7?,11?-dimethyl-17?-hydroxyestr-4-en-3-one 17-undecanoate, and processes for their preparation.Type: ApplicationFiled: February 7, 2011Publication date: August 11, 2011Applicants: ServicesInventors: Richard P. Blye, Hyun K. Kim
-
Publication number: 20110189160Abstract: Methods and compositions for treating skin conditions in animals, which tend to have higher skin pH than humans, including wounds, ulcers, rashes, burns, abrasions, and other irritations and relevant injuries are provided. The invention contemplates the use of an aqueous or emollient medium having non-occlusive properties with one or more pH raising ingredients in a composition specifically designed to deliver oxygen to the skin's surface.Type: ApplicationFiled: September 10, 2010Publication date: August 4, 2011Inventor: Jennifer Bartels
-
Publication number: 20110190201Abstract: A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on pre-menopausal cyclic steroid hormone levels of the subject and on current cyclic steroid hormone levels of the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject.Type: ApplicationFiled: March 10, 2011Publication date: August 4, 2011Applicant: Searete LLCInventors: Roderick A. Hyde, Muriel Y. Ishikawa, Dennis J. Rivet, Elizabeth A. Sweeney, Lowell L. Wood, JR., Victoria Y.H. Wood
-
Publication number: 20110182891Abstract: A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95% by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form.Type: ApplicationFiled: June 30, 2009Publication date: July 28, 2011Applicant: Abbott GmbH & Co., KGInventors: Bernd Liepold, Jörg Breitenbach, Markus Mägerlein, Claudia Packhäuser, Thomas K. Kessler
-
Publication number: 20110166060Abstract: The present invention provides compositions and methods for noninvasive delivery of therapeutic agents across an intact tympanic membrane. For example, the compositions include a penetration enhancer which increases the flux of a therapeutic agent (e.g., antibiotic) across the tympanic membrane. Such compositions are particularly useful in the treatment of otitis media. Additionally, the composition may include a sustained release agents that, in some embodiments form sustained release reservoirs, in situ, once administered to a patient.Type: ApplicationFiled: May 19, 2009Publication date: July 7, 2011Applicants: Massachusettes Institute of Technology, Children's Medical Center CorporationInventors: Emmanuel John Simons, Todd R. Hoare, Daniel S. Kohane, Robert S. Langer
-
Publication number: 20110165259Abstract: [Problem to be Solved] The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. [Solution] A method for producing a composite organic compound powder for medical use is used which comprises: mixing a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxyvinyl polymer and fine-pulverizing the organic compound powder; and removing at least the salt and the polyol during or after fine-pulverizing.Type: ApplicationFiled: September 15, 2009Publication date: July 7, 2011Applicant: ACTIVUS PHARMA CO., LTD.Inventors: Takashi Hirokawa, Takahiro Tada, Jun Nihira
-
Publication number: 20110158920Abstract: A method for producing a bigel, the method comprising: (a) providing an oleogel comprising at least one oily agent gelled with at least one cellulose polymer; (b) providing an aqueous gel comprising at least one component whose viscosity is pH dependent, such as a carbomer; (c) mixing the oleogel and the aqueous gel together to form a bigel; and (d) subsequently adjusting the viscosity of the bigel under high flow and low shear stirring to obtain a bigel of a desired viscosity.Type: ApplicationFiled: December 31, 2007Publication date: June 30, 2011Applicant: ARDANA BIOSCIENCE LIMITEDInventors: Timothy Morley, Julian Robert Walker Fisher